Related Experiment Video

Updated: Jul 7, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Cell signaling modifiers in prostate cancer

Franklin L Chen1, Andrew J Armstrong, Daniel J George

  • 1Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. franklin.chen@duke.edu

Cancer Journal (Sudbury, Mass.)
|February 28, 2008
PubMed

Insights

Targeted therapies, including ErbB inhibitors and mammalian target of rapamycin (mTOR) inhibitors, show promise for hormone-refractory prostate cancer (HRPC). Further research is needed to optimize their use as standalone treatments or sensitizers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Hormone-refractory prostate cancer (HRPC) has limited treatment options after progression on hormone therapy and chemotherapy.
  • Advances in docetaxel chemotherapy offer some benefit, but further therapeutic strategies are needed.
  • ErbB-targeted therapies show potential but require identification of patient subgroups for efficacy.

Purpose of the Study:

  • To explore the potential of targeted therapies, specifically ErbB receptor tyrosine kinase and mammalian target of rapamycin (mTOR) pathway inhibitors, in HRPC treatment.
  • To investigate the role of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss in HRPC and its potential reversal by mTOR inhibition.
  • To determine the efficacy of these targeted agents as monotherapies or as chemo- and radiosensitizers.

Main Methods:

  • Preclinical studies investigating mTOR inhibition in the context of PTEN loss.
  • Review of existing clinical trial data (TAX 327, SWOG 99-16) for HRPC treatment outcomes.
  • Exploration of targeted inhibition strategies against ErbB family kinases and downstream mTOR pathway.

Main Results:

  • Preclinical data suggest mTOR inhibition can reverse the phenotype associated with PTEN loss.
  • Efficacy of ErbB-targeted therapies in HRPC is limited by unknown patient susceptibility factors.
  • Further investigation into targeted receptor tyrosine kinase and mTOR inhibition is warranted.

Conclusions:

  • Targeted inhibition of receptor tyrosine kinases and mTOR pathways represents a promising avenue for HRPC treatment.
  • These targeted agents may function as effective tumoricidal drugs or enhance the efficacy of chemotherapy and radiotherapy.
  • Identifying predictive biomarkers for ErbB-targeted therapies is crucial for clinical application in HRPC.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...